Bioventus (NYSE:BVS) PT Raised to $17.00

Bioventus (NYSE:BVS) had its price target hoisted by Craig Hallum from $12.00 to $17.00 in a research note issued to investors on Friday morning, Benzinga reports. Craig Hallum currently has a buy rating on the stock.

Separately, Canaccord Genuity Group raised their price target on shares of Bioventus from $8.00 to $12.00 and gave the stock a buy rating in a research note on Tuesday, August 13th.

Bioventus Price Performance

BVS opened at $11.95 on Friday. Bioventus has a 1 year low of $2.85 and a 1 year high of $12.41. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.33 and a quick ratio of 0.96. The company has a market capitalization of $946.03 million, a price-to-earnings ratio of -34.14 and a beta of 0.89. The firm’s fifty day moving average price is $9.32 and its two-hundred day moving average price is $6.94.

Bioventus (NYSE:BVS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.07 by $0.12. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. The firm had revenue of $151.22 million during the quarter, compared to analyst estimates of $137.70 million. During the same quarter last year, the business posted $0.14 EPS. As a group, analysts anticipate that Bioventus will post 0.4 earnings per share for the current fiscal year.

Insider Transactions at Bioventus

In related news, Director John A. Bartholdson bought 25,500 shares of the business’s stock in a transaction on Monday, August 19th. The stock was acquired at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the purchase, the director now directly owns 6,939,357 shares in the company, valued at $59,331,502.35. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director John A. Bartholdson bought 25,500 shares of the stock in a transaction on Monday, August 19th. The shares were acquired at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the purchase, the director now directly owns 6,939,357 shares of the company’s stock, valued at approximately $59,331,502.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John A. Bartholdson acquired 80,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was bought at an average price of $8.55 per share, for a total transaction of $684,000.00. Following the completion of the transaction, the director now owns 6,913,857 shares of the company’s stock, valued at approximately $59,113,477.35. The disclosure for this purchase can be found here. Corporate insiders own 32.90% of the company’s stock.

Institutional Trading of Bioventus

Hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC lifted its stake in Bioventus by 13.8% in the second quarter. Squarepoint Ops LLC now owns 26,171 shares of the company’s stock worth $150,000 after acquiring an additional 3,170 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Bioventus during the first quarter valued at $28,000. Hillsdale Investment Management Inc. lifted its holdings in shares of Bioventus by 26.1% during the 1st quarter. Hillsdale Investment Management Inc. now owns 34,742 shares of the company’s stock valued at $181,000 after buying an additional 7,200 shares during the period. Lazard Asset Management LLC bought a new stake in Bioventus during the first quarter valued at approximately $40,000. Finally, GSG Advisors LLC increased its stake in shares of Bioventus by 55.8% in the 1st quarter. GSG Advisors LLC now owns 26,511 shares of the company’s stock worth $133,000 after purchasing an additional 9,500 shares in the last quarter. 62.94% of the stock is owned by institutional investors.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.